Single Ascending Dose Tolerability Study of DG3173

NCT02217488 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: DG3173
DRUG: Placebo

Sponsor

Aspireo Pharmaceuticals Limited

Collaborators

[object Object]